Comparison 1. Aripiprazole versus typical antipsychotic drugs(short term </=12 weeks).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death	3	955	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Global state	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Improvement in CGI‐S score	1	300	Mean Difference (IV, Random, 95% CI)	0.0 [‐0.28, 0.28]
2.2 CGI‐I score	1	300	Mean Difference (IV, Random, 95% CI)	‐0.20 [‐0.48, 0.08]
3 Mental state	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Lack of clinically significant response to treatment	6	1447	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.83, 1.24]
3.2 Lack of clinically significant response to treatment (subgroup excluding the two smallest studies)	4	1263	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.89, 1.06]
4 Mental state	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Improvement in BPRS total score	2	412	Mean Difference (IV, Random, 95% CI)	1.07 [‐2.09, 4.22]
4.2 Improvement in PANSS total score	1	300	Mean Difference (IV, Random, 95% CI)	0.70 [‐4.13, 5.53]
5 Adverse effects : extra‐pyramidal symptoms	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 EPS‐related adverse event	3	968	Risk Ratio (M‐H, Random, 95% CI)	0.46 [0.25, 0.87]
5.2 Akathisia	3	903	Risk Ratio (M‐H, Random, 95% CI)	0.39 [0.25, 0.60]
5.3 Hypertonia	2	603	Risk Ratio (M‐H, Random, 95% CI)	0.49 [0.04, 6.28]
5.4 Tremor	1	308	Risk Ratio (M‐H, Random, 95% CI)	0.36 [0.12, 1.12]
6 Adverse effects : other symptoms	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 Abdominal pain	1	308	Risk Ratio (M‐H, Random, 95% CI)	1.27 [0.51, 3.19]
6.2 Abnormal total CPK levels	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.63 [0.66, 4.01]
6.3 Agitation	3	955	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.63, 1.54]
6.4 Anxiety	2	608	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.65, 1.40]
6.5 Asthenia (Tiredness)	1	308	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.32, 2.67]
6.6 Blurred vision	1	308	Risk Ratio (M‐H, Random, 95% CI)	0.19 [0.05, 0.71]
6.7 Clinically significantly raised prolactin levels	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.07 [0.03, 0.16]
6.8 Dizziness	3	963	Risk Ratio (M‐H, Random, 95% CI)	1.88 [1.11, 3.21]
6.9 Dyspepsia	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.69 [0.77, 3.69]
6.10 Headache	4	1263	Risk Ratio (M‐H, Random, 95% CI)	1.32 [0.84, 2.06]
6.11 Increase in CPK levels	1	300	Risk Ratio (M‐H, Random, 95% CI)	2.13 [0.67, 6.78]
6.12 Insomnia	3	968	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.54, 1.30]
6.13 Nausea	3	963	Risk Ratio (M‐H, Random, 95% CI)	3.03 [1.51, 6.05]
6.14 Orthostatic hypotension	1	308	Risk Ratio (M‐H, Random, 95% CI)	4.59 [0.59, 35.73]
6.15 Pain at injection site	2	655	Risk Ratio (M‐H, Random, 95% CI)	2.80 [0.69, 11.31]
6.16 Psychosis	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.58 [0.71, 3.50]
6.17 QTc abnormalities	4	1263	Risk Ratio (M‐H, Random, 95% CI)	0.37 [0.03, 4.39]
6.18 Sinus tachycardia	1	295	Risk Ratio (M‐H, Random, 95% CI)	0.09 [0.01, 0.80]
6.19 Somnolence	4	1263	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.43, 1.00]
6.20 Tachycardia	1	295	Risk Ratio (M‐H, Random, 95% CI)	2.30 [0.30, 17.79]
6.21 Vomiting	2	603	Risk Ratio (M‐H, Random, 95% CI)	1.30 [0.67, 2.51]
6.22 Weight gain	1	308	Risk Ratio (M‐H, Random, 95% CI)	0.56 [0.25, 1.28]
7 Satisfaction with treatment : leaving study early due to withdrawal of consent	4	919	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.50, 0.99]
8 Quality of life : incidence of non‐improvement of QLS score	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.71, 0.94]
9 Concomitant drug treatment	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 Antimuscarinic medication	2	412	Risk Ratio (M‐H, Random, 95% CI)	0.13 [0.00, 9.63]
9.2 Antipsychotics	1	308	Risk Ratio (M‐H, Random, 95% CI)	0.51 [0.17, 1.54]
9.3 Benzodiazepines	1	360	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.36, 1.27]
10 Leaving study early	7		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 Discontinuation due to any reason	7	1686	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.76, 1.10]
10.2 Discontinuation due to adverse event including psychosis	6	1326	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.68, 1.65]
10.3 Discontinuation due to lack of efficacy	5	1214	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.74, 1.82]
10.4 Discontinuation due to marked deterioration	3	423	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.33, 2.46]
10.5 Discontinuation due to non‐compliance with study protocol	2	311	Risk Ratio (M‐H, Random, 95% CI)	1.79 [0.19, 16.93]